CN120282795A - Omicron冠状病毒疫苗构建体及其制备和使用方法 - Google Patents

Omicron冠状病毒疫苗构建体及其制备和使用方法 Download PDF

Info

Publication number
CN120282795A
CN120282795A CN202380033194.2A CN202380033194A CN120282795A CN 120282795 A CN120282795 A CN 120282795A CN 202380033194 A CN202380033194 A CN 202380033194A CN 120282795 A CN120282795 A CN 120282795A
Authority
CN
China
Prior art keywords
cov
sars
chad
mice
adenoviral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380033194.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·迪亚摩德
I·德米特里耶夫
A·哈桑
D·居里尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN120282795A publication Critical patent/CN120282795A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380033194.2A 2022-02-02 2023-02-02 Omicron冠状病毒疫苗构建体及其制备和使用方法 Pending CN120282795A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263305979P 2022-02-02 2022-02-02
US63/305979 2022-02-02
US202263375803P 2022-09-15 2022-09-15
US63/375803 2022-09-15
US202263384075P 2022-11-16 2022-11-16
US63/384075 2022-11-16
US202263434815P 2022-12-22 2022-12-22
US63/434815 2022-12-22
PCT/US2023/061878 WO2023150638A2 (en) 2022-02-02 2023-02-02 Omicron coronavirus vaccine constructs and methods of making and using same

Publications (1)

Publication Number Publication Date
CN120282795A true CN120282795A (zh) 2025-07-08

Family

ID=87552962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380033194.2A Pending CN120282795A (zh) 2022-02-02 2023-02-02 Omicron冠状病毒疫苗构建体及其制备和使用方法

Country Status (7)

Country Link
EP (1) EP4473122A4 (https=)
JP (1) JP2025508676A (https=)
KR (1) KR20240137110A (https=)
CN (1) CN120282795A (https=)
AU (1) AU2023216258A1 (https=)
CA (1) CA3243465A1 (https=)
WO (1) WO2023150638A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
CN116987184B (zh) * 2023-09-26 2024-01-12 北京百普赛斯生物科技股份有限公司 新型冠状病毒bq.1.1突变株特异性抗体及其应用
WO2025202543A1 (en) * 2024-03-28 2025-10-02 Rokote Laboratories Finland Oy A vaccine composition comprising an adenoviral vector and an adenoviral vector delivery enhancing agent
WO2025250851A1 (en) * 2024-05-29 2025-12-04 Washington University Trivalent pan-sarbecovirus mucosal vaccine constructs and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716928C (en) * 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
CA3167833A1 (en) * 2020-02-14 2021-08-19 Bertrand Victor Gilbert GEORGES Coronavirus immunogenic compositions and uses thereof
MX2022013934A (es) * 2020-05-07 2023-02-22 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
WO2021247567A1 (en) * 2020-06-01 2021-12-09 Washington University Coronavirus vaccine constructs and methods of making and using same

Also Published As

Publication number Publication date
EP4473122A4 (en) 2026-03-04
AU2023216258A1 (en) 2024-08-01
WO2023150638A2 (en) 2023-08-10
EP4473122A2 (en) 2024-12-11
JP2025508676A (ja) 2025-04-10
WO2023150638A3 (en) 2023-09-14
CA3243465A1 (en) 2023-08-10
KR20240137110A (ko) 2024-09-19

Similar Documents

Publication Publication Date Title
US11382968B2 (en) Coronavirus immunogenic compositions and uses thereof
CN120282795A (zh) Omicron冠状病毒疫苗构建体及其制备和使用方法
US20210077614A1 (en) Trimeric s1-cd40l fusion protein vaccine against middle east respiratory syndrome-coronavirus
US10059747B2 (en) Crimean-congo haemorrhagic fever virus antigenic composition
US20210260181A1 (en) Coronavirus immunogenic compositions and uses thereof
EP4106809A1 (en) Vaccine compositions for preventing coronavirus disease
JP2023531554A (ja) 呼吸器合胞体ウイルス感染に対するワクチンの組み合わせ
US20250000968A1 (en) Sars-cov-2 spike fused to a hepatitis b surface antigen
JP2024530047A (ja) ワクチン抗原
US20230227848A1 (en) Coronavirus vaccine constructs and methods of making and using same
JP2024520730A (ja) コロナウイルスに対するウイルス様粒子ワクチン
US20220275346A1 (en) Hantavirus antigenic composition
US20250049912A1 (en) Multicistronic Vaccine and Methods for Producing and Using the Same
US20240293532A1 (en) Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use
WO2026030724A1 (en) Sars-cov-2 vaccine
WO2023154402A2 (en) Compositions and methods for fcrn-targeted intranasal coronavirus vaccination
CN120019142A (zh) 水疱性口炎病毒马尔堡病毒疫苗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination